ad image

Company Info

Pfizer

Pfizer

Drug Discovery & Development

Overview

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.
Pfizer
Contributions
45 Contributions1 / 3
Pfizer
COVID-19 Vaccine

Pfizer and BioNTech to Vaccinate Olympic Athletes in Tokyo

Pfizer

PR-M05-21-014May 20, 2021
Pfizer
Emergency Use

Pfizer and BioNtech Receive First U.S. Authorization for Emergency Use of Covid-19 Vaccine in Adolescents

Pfizer

PR-M05-21-007May 11, 2021
Pfizer
COVID-19

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study

Pfizer

PR-M11-20-007Nov 10, 2020
Pfizer
COVID-19 Vaccine

Pfizer and BioNTech Announce Data from Preclinical Studies of COVID-19 Vaccine Candidate

Pfizer

PR-M09-20-NI-15Sep 11, 2020
Pfizer
COVID-19 Vaccine

Pfizer and BioNTech to Receive $2 Billion from U.S. Government

Pfizer

PR-M07-20-NI-33-1383Jul 23, 2020
Pfizer
COVID-19 Vaccine

Pfizer and BioNTech Report T Cell Response in COVID-19 Vaccine

Pfizer

PR-M07-20-NI-30Jul 21, 2020
Pfizer
COVID-19 Vaccine

Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2

Pfizer

PR-M06-20-NI-042Jul 02, 2020
Pfizer
Investment

Pfizer Establishes New Program to Support Continued Biotechnology Innovation

Pfizer

PR-M06-20-NI-001Jun 02, 2020
Pfizer
Licensing Agreement

Akcea and Pfizer Inc. Announce Licensing Agreement for Investigative Antisense Therapy Akcea-ANGPTL3-LRX

Pfizer

PR-M10-19-NI-020Oct 11, 2019
Pfizer
Leadership

Ian Read to Retire as Executive Chairman of Pfizer’s Board of Directors; Chief Executive Officer Dr. Albert Bourla Named Chairman

Pfizer

PR-M09-19-NI-053Sep 27, 2019
Pfizer
Vaccine

Pfizer Announces Positive Preliminary Results from a 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate for Disease Prevention in Infants

Pfizer

PR-M09-19-NI-028Sep 11, 2019
Pfizer
Recall

Pfizer Inc. Issues A Voluntary Nationwide Recall For 2 Lots of RELPAX® Due to Potential Microbiological Contamination of Non-Sterile Product

Pfizer

PR-M08-19-NI-048Aug 16, 2019
Pfizer
M&A

Mylan and Upjohn, a Division Of Pfizer, to Combine

Pfizer

PR-M07-19-NI-079Jul 31, 2019
Pfizer
M&A

Pfizer Completes Acquisition of Array Biopharma

Pfizer

PR-M07-19-NI-080Jul 31, 2019
Pfizer
Clinical Data

Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD)

Pfizer

PR-M07-19-NI-017Jul 08, 2019
Pfizer
FDA Approval

Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr)

Pfizer

PR-M07-19-NI-015Jul 08, 2019
Pfizer

Pfizer Announces Positive Top-Line Results from Phase 3 Study in Patients with Moderate to Severe Atopic Dermatitis

Pfizer

PR-M05-19-NI-055May 20, 2019
Pfizer
Drug Approval

U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease

Pfizer

PR-M05-19-NI-036May 13, 2019
Pfizer
Positive Opinion

Pfizer Receives Positive CHMP Opinion for TALZENNA®(talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer

Pfizer

PR-M04-19-NI-086Apr 29, 2019
Pfizer
Oncology

Pfizer Receives Positive CHMP Opinion for LORVIQUA® (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer

Pfizer

PR-M03-19-NI-005Mar 04, 2019
1 / 3
0 Contributors1 / 0

No authors found

1 / 0